{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.3","value":"-0.6"},{"groupId":"OG001","spread":"1.9","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Right Median Wrist"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.6","value":"-0.2"},{"groupId":"OG001","spread":"2.1","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Left Median Wrist"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0","value":"-0.8"},{"groupId":"OG001","spread":"2.1","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Right Median Elbow"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0","value":"0"},{"groupId":"OG001","spread":"1.6","value":"-0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Left Median Elbow"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4","value":"0.4"},{"groupId":"OG001","spread":"1.7","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Right Tibial Ankle"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.0","value":"0.8"},{"groupId":"OG001","spread":"2.1","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Left Tibial Ankle"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Change in tibial motor response from baseline to 8 weeks will include tibial amplitude (mV)","dispersionType":"Standard Deviation","groups":[{"description":"VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG000","title":"Grade 2-3 Established Neuropathy"},{"description":"VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG001","title":"Grade 1-2 New-onset Neuropathy"}],"paramType":"MEAN","populationDescription":"The number in this outcome was determined by the number of participants completing both baseline and 8 week evaluations. Unable to collect amplitude for the ankle on one participant.","reportingStatus":"POSTED","timeFrame":"Baseline, 8 weeks","title":"Change in Motor Nerve Function (Tibial Amplitude) From Baseline to 8 Weeks","type":"SECONDARY","unitOfMeasure":"mV"}